Orion b Aktie
| 52,46EUR | 1,70EUR | 3,35% |
WKN DE: A0J3QM / ISIN: FI0009014377
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 43,48 |
| Hesham M. Gad, MBA | 31,01 |
| Donna Van Allen | 18,79 |
| Kevin Ting | 5,84 |
| DFA International Core Equity Fund | 3,11 |
| MFC Property & Infrastructure Flexible Income Fund | 1,30 |
| Jack Howard Jacobs | 0,63 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 3 265 | 3 311 | 3 355 | 3 527 | 3 632 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,32 | 0,33 | 0,31 | 0,38 | 0,33 |
Bilanz (in Mio. EUR) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 600 | 744 | 690 | 879 | 825 |
| Summe Anlagevermögen | 436 | 372 | 424 | 625 | 621 |
| Summe Aktiva | 1 036 | 1 116 | 1 114 | 1 504 | 1 446 |
Bilanz (in Mio. EUR) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 256 | 384 | 366 | 596 | 556 |
| Summe Eigenkapital | 779 | 731 | 748 | 908 | 890 |
| Summe Passiva | 1 036 | 1 116 | 1 114 | 1 504 | 1 446 |
Adresse
| Orionintie 1A, 02200 Espoo | |
| Telefon | +358 (10) 4261 |
| Internet | http://www.orion.fi |
Management
|
Aino Anna Liisa Hurme
President & Chief Executive Officer |
|
Ari Tapio Lehtoranta
Independent Director |
|
Eija Ronkainen
Independent Director |
|
Heikki Joensuu
Vice President-Therapy Area Oncology, R&D |
|
Henrik Stenqvist
Director |
|
Hilpi Rautelin
Vice Chairman |
|
Johanna Ivaska
Dir-Orion Rsch Center for Biotech & Trnsltnl Rsch |
|
Juhani Kankaanpaa
Senior Vice President-Global Operations |
|
Jukka Muhonen
Director-Global Business Development |
|
Julia Macharey
Senior Vice President-People & Culture |
|
Karen Lykke Sörensen
Director |
|
Kari Jussi Aho
Independent Director |
|
Maziar Mike Doustdar
Director |
|
Mikko Kemppainen
Head-Legal Affairs |
|
Olli Huotari
Secretary & Senior VP-Corporate Functions |
|
Outi Vaarala
SVP-Innovative Medicines, Research & Development |
|
Paula Rytilä
Head-Region Asia Pacific |
|
René Lindell
Chief Financial Officer |
|
Satu Maarit Ahomäki
Senior VP-Generics & Consumer Health |
|
Sinikka Markkula
Chief Information Officer |
|
Tero Närvänen
Vice President-Quality Management |
|
Tuukka Hirvonen
Head-Investor Relations |
|
Veli-Matti Johannes Mattila
Chairman |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.